Information Provided By:
Fly News Breaks for August 17, 2018
JAZZ
Aug 17, 2018 | 07:31 EDT
Leerink analyst Ami Fadia raised Jazz Pharmaceuticals for solriamfetol based on results from the firm's MEDACorp physician survey on the Excessive Sleepiness market. Fadia continues to see solriamfetol as a key growth asset in the outer years when Xyrem faces competition. The analyst rates Jazz an Outperform and increased its price target to $210 from $200.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.